Cardio Diagnostics Partners with Aimil and Dr. Lal PathLabs to Introduce PrecisionCHD Test Across India
First International Expansion Brings Advanced Heart Disease Detection to India
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) has announced a strategic partnership with Aimil Ltd. and Dr. Lal PathLabs Limited to launch the PrecisionCHD test in India. This move signifies Cardio Diagnostics’ first expansion outside the U.S. and aims to improve the identification and management of coronary heart disease (CHD) in a market where cardiovascular disease is a leading and growing concern.
Addressing an Urgent Health Challenge in India
Heart disease remains a major public health challenge in India, with CHD prevalence rates reported at up to 7.4% in rural areas and as high as 13% in urban regions. By pairing Aimil’s extensive healthcare distribution network and Dr. Lal PathLabs’ over 290 clinical laboratories and 300+ MD pathologists, this collaboration targets both large-scale reach and clinical expertise. The initial rollout focuses on integrating the PrecisionCHD test into Dr. Lal PathLabs’ laboratory network while aligning with Indian clinical and regulatory standards. A broader commercial launch is targeted for 2026.
PrecisionCHD: A Molecular-Level Edge for Early and Non-Obstructive CHD Detection
PrecisionCHD stands out among CHD diagnostics as a clinically validated blood test that uses epigenetics, genetics, and artificial intelligence (AI) to detect coronary heart disease at a molecular level. Unlike angiograms, which primarily identify obstructive disease, PrecisionCHD can also detect non-obstructive CHD forms, including Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA)—conditions that are often missed during standard imaging. These capabilities were recently validated at the American Heart Association Scientific Sessions in New Orleans, LA.
| Key Partnership Facts | Details |
|---|---|
| Companies Involved | Cardio Diagnostics, Aimil Ltd., Dr. Lal PathLabs |
| Test Introduced | PrecisionCHD (AI-driven molecular CHD detection) |
| Network Reach | 290+ labs, 300+ MD pathologists (Dr. Lal PathLabs) |
| Urban Prevalence of CHD in India | 13% |
| Rural Prevalence of CHD in India | Up to 7.4% |
| Commercial Rollout Timeline | Expected 2026 |
Collaboration Aims to Transform Early Detection and Personalized Treatment
The partnership is poised to democratize access to advanced diagnostics across India. By enabling molecular-level detection—even in cases missed by standard imaging—PrecisionCHD may help physicians identify disease earlier and tailor treatment for better outcomes. Leadership from all three companies has emphasized the importance of this launch for both democratizing healthcare and establishing India as a primary market for next-generation diagnostic innovation.
Looking Ahead: A Step Towards Global Precision Medicine
This initiative marks the latest commitment by Cardio Diagnostics to expand its global footprint and respond to the critical need for early, actionable detection of heart disease. With the anticipated growth of the rollout and ongoing integration efforts, all eyes will be on India as the country takes significant steps to improve cardiovascular patient outcomes through cutting-edge molecular technology.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI